1 recruiting, 1 withdrawn. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 1, Withdrawn 1 |
Follow HRD: new trials by email Literature Review of HRD trials Research Report on HRD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma Niraparib, Dostarlimab - HRD, Cholangiocarcinoma | Phase 2 | Withdrawn | Walid Shaib, MD | 2021-10-11 | 2022-06-29 | |
| PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer AZD6738, Olaparib, Durvalumab - Breast Neoplasm, Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | Institute of Cancer Research, United Kingdom | 119 | 2019-10-15 | 2025-08-11 |
Breast Neoplasms (1) · Cholangiocarcinoma (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (2) · Adenocarcinoma (1) · Breast Diseases (1) · Carcinoma (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Skin Diseases (1) · Skin and Connective Tissue Diseases (1)
ceralasertib (1) · dostarlimab (1) · durvalumab (1) · niraparib (1) · olaparib (1)
Institute of Cancer Research, United Kingdom (1) · Walid Shaib, MD (1)
United Kingdom (1)
Andrew Tutt (1) · Walid Shaib, MD (1)
2018 (1)